Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 15Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Chronic-Phase 10Recurrence 8Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Neoplasm Metastasis 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Burkitt Lymphoma 5Pancreatic Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasms 3Lymphoma 3Gliosarcoma 3Sarcoma 2Salivary Gland Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Polycythemia Vera 2Oligodendroglioma 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Rituximab 49fludarabine phosphate 32Cyclophosphamide 30Whole-Body Irradiation 26Peripheral Blood Stem Cell Transplantation 25Mycophenolic Acid 24Tacrolimus 19Cyclosporine 16Dexamethasone 13Busulfan 13ibrutinib 12Sirolimus 12Bortezomib 11Antilymphocyte Serum 11Melphalan 10Etoposide 10Calcium Dobesilate 10Methotrexate 8Lenalidomide 8Cyclosporins 8idelalisib 7Everolimus 6Indium 5Filgrastim 5thymoglobulin 4ibritumomab tiuxetan 4carfilzomib 4Vincristine 4Prednisone 4In Situ Hybridization, Fluorescence 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Waldenstrom Macroglobulinemia × Dasatinib × Clear all
NCT04115059 2024-03-21

Dasatinib In Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled 13 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡